Axsome Therapeutics, Inc. (AXSM) Stock AnalysisAXSMAxsome Therapeutics, Inc.

Axsome Therapeutics, Inc. is a fully integrated biopharmaceutical company. The Company focused on developing medicines for people impacted by central nervous system (CNS) conditions. Its commercial products include AUVELITY, SUNOSI, and SYMBRAVO. It is also advancing pipeline of novel product candidates in early- to late-stage development addressing a broad range of serious neurological and psychiatric conditions. Its product pipelines include AXS-05, AXS-12, and AXS-14. Its lead product candidate, AXS-05 (dextromethorphan-bupropion), is developed for the treatment of Alzheimer’s disease (AD) agitation and smoking cessation. Its AXS-12 (reboxetine) is a novel, oral, potent, highly selective investigational norepinephrine reuptake inhibitor (NRI) and cortical dopamine modulator being developed for the treatment of narcolepsy. Its AXS-14 (esreboxetine) is a novel, oral, potent, highly selective investigational NRI being developed for the management of fibromyalgia. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Axsome Therapeutics is currently a hold. The stock is trading at $168.35 with a forward P/E ratio of 32.15, indicating potential for growth, but it has a low RSI of 7.84, suggesting it is oversold. The company reported a significant revenue increase of 66% year-over-year, reaching approximately $638.5 million for FY 2025, but it still faces challenges with a net loss of $183.2 million, which raises concerns about profitability.

2 analysts cover AXSM: 2 rate it Buy, 0 Hold and 0 Sell. The average price target is 209.54.